Latest Industry Insights

At the European Laboratory Research and Innovation Group’s (ELRIG) Research and Innovation 2024 event, we asked a selection of start-up companies in the biotech space the same question: what are the key challenges you currently face?

We spoke with Dr. Bryan Oronsky, chief development officer at EpicentRx, to discover more about the promise of multipurpose drugs and the potential of EpicentRx’s nibrozetone (RRx-001) for several conditions.

The industry's search for alternatives to traditional preclinical drug testing methods has led to a growing interest in the potential of three-dimensional (3D) in vitro models. To delve deeper into this subject, Technology Networks spoke with Madhu Lal-Nag, chief scientific officer at InSphero, a 3D in vitro model company with a mission to “modernize drug discovery in ways that inspire researchers everywhere to reach their full potential and fuel a new era of breakthrough therapies.”

In this interview, Dr. Mason tells us about her career path and experiences along the way, as well as sharing advice for women considering a career in science.

We spoke to Olivier Barberan, director of Translational Medicine Solutions at Elsevier, to find out more about how predictive tools can inform pharma companies and help pave the way for drugs to get to market.

Encouraging scientists to rethink the materials and methods they use will help to foster a culture of sustainability within research institutions and across various industries. Technology Networks spoke with Dr. Joel Eichmann from Green Elephant Biotech to learn more about the creation of its plant-based plastic labware, and his broader vision for embedding sustainability within the biotech industry.

To find out more about AI in pharma, Technology Networks spoke with Roger Palframan, head of US Research and digital for Early Solutions at UCB.

In this interview, Dr. Jason Park, co-founder and CEO of Empress Therapeutics, tells us more about the Chemilogics platform and the benefits this approach to drug discovery can offer.

As the use of generative AI tools expands, and their potential in scientific research is better understood, there are ethical considerations to be made. Dr. Dror Kolodkin-Gal explores some of the issues and potential solutions.

In this interview, Technology Networks spoke to Heiko Neuweger, director of Bioinformatics Life Science Mass Spectrometry Software R&D at Bruker, to learn about the importance of target compound annotation and identification, the advantages of integrating collision cross section (CCS) information into workflows and the benefits of CCS-Predict Pro.